n6022 profile

N6022: inhibits S-nitrosoglutathione reductase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	44623946
CHEMBL ID	1738699
SCHEMBL ID	244480
MeSH ID	M0572731

Synonym
CHEMBL1738699 ,
n-6022
n6022
3-{1-(4-carbamoyl-2-methylphenyl)-5-[4-(1h-imidazol-1-yl)phenyl]-1h-pyrrol-2-yl}propanoic acid
bdbm50354475
S7589
SCHEMBL244480
HY-14984
CS-2034
3-(5-(4-(1h-imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1h-pyrrol-2-yl)propanoic acid
80liu5p95d ,
unii-80liu5p95d
n 6022
1208315-24-5
3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid
YVPGZQLRPAGKLA-UHFFFAOYSA-N ,
AC-33166
1-[4-(aminocarbonyl)-2-methylphenyl]-5-[4-(1h-imidazol-1-yl)phenyl]-1h-pyrrole-2-propanoic acid
J-690065
EX-A343
AKOS030526322
3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1h-imidazol-1-yl)phenyl]-1h-pyrrol-2-yl]propanoic acid
HMS3653J15
NCGC00378558-04
SW219745-1
DB12206
FT-0700115
BS-14950
BCP09367
n-6022;n 6022
SB19680
HMS3746K09
CCG-268815
Q27269159
DTXSID801025710

Excerpt	Reference	Relevance
"N6022 is a novel, first-in-class drug with potent inhibitory activity against S-nitrosoglutathione reductase (GSNOR), an enzyme important in the metabolism of S-nitrosoglutathione (GSNO) and in the maintenance of nitric oxide (NO) homeostasis. "	( Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Chun, LE; Green, LS; Patton, AK; Richards, JP; Rosenthal, GJ; Sun, X, 2012)	2.12

Excerpt	Reference	Relevance
"N6022 (5 mg/kg; iv) treatment of IR mice at 2 h after reperfusion followed by the treatment of the same dose daily for 3 days reduced the infarct volume and decreased the neurological score."	( Targeting GSNOR for functional recovery in a middle-aged mouse model of stroke. Feng, W; Islam, SMT; Khan, M; Kumar, P; Qiao, F; Singh, AK; Singh, I; Won, JS, 2020)	1.28
"N6022 treatment also attenuated the OVA-induced increase in NFκB activation."	( Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation. Blonder, JP; Boyanapalli, R; Delany, C; Green, LH; Look, K; Looker, D; Mehra, NK; Mutka, SC; Qiu, J; Richards, JP; Rosenthal, GJ; Scoggin, C; Sun, X; Suniga, M, 2014)	1.12

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	1.6933	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	3.3786	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	0.9522	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	3.3786	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	3.3786	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	3.3786	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	3.3786	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0001	1.7536	10.0000	AID1414305
Alcohol dehydrogenase class-3	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0200	0.0200	0.0200	AID1414305
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	0.7700	0.0000	2.3983	10.0000	AID621422; AID645728
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	INH	100.0000	7.4000	7.4000	7.4000	AID645729
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
retinoid metabolic process	Alcohol dehydrogenase class-3	Homo sapiens (human)
respiratory system process	Alcohol dehydrogenase class-3	Homo sapiens (human)
fatty acid omega-oxidation	Alcohol dehydrogenase class-3	Homo sapiens (human)
response to lipopolysaccharide	Alcohol dehydrogenase class-3	Homo sapiens (human)
positive regulation of blood pressure	Alcohol dehydrogenase class-3	Homo sapiens (human)
response to nitrosative stress	Alcohol dehydrogenase class-3	Homo sapiens (human)
response to redox state	Alcohol dehydrogenase class-3	Homo sapiens (human)
formaldehyde catabolic process	Alcohol dehydrogenase class-3	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
fatty acid binding	Alcohol dehydrogenase class-3	Homo sapiens (human)
zinc ion binding	Alcohol dehydrogenase class-3	Homo sapiens (human)
electron transfer activity	Alcohol dehydrogenase class-3	Homo sapiens (human)
formaldehyde dehydrogenase activity	Alcohol dehydrogenase class-3	Homo sapiens (human)
identical protein binding	Alcohol dehydrogenase class-3	Homo sapiens (human)
S-(hydroxymethyl)glutathione dehydrogenase (NAD(P)+) activity	Alcohol dehydrogenase class-3	Homo sapiens (human)
S-(hydroxymethyl)glutathione dehydrogenase (NADP+) activity	Alcohol dehydrogenase class-3	Homo sapiens (human)
S-(hydroxymethyl)glutathione dehydrogenase (NAD+) activity	Alcohol dehydrogenase class-3	Homo sapiens (human)
alcohol dehydrogenase (NAD+) activity, zinc-dependent	Alcohol dehydrogenase class-3	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
mitochondrion	Alcohol dehydrogenase class-3	Homo sapiens (human)
cytosol	Alcohol dehydrogenase class-3	Homo sapiens (human)
extracellular exosome	Alcohol dehydrogenase class-3	Homo sapiens (human)
cytosol	Alcohol dehydrogenase class-3	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (87)

Assay ID	Title	Year	Journal	Article
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID601752	Inhibition of human recombinant A1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601757	Inhibition of human recombinant beta1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601774	Inhibition of human recombinant MT1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID1414305	Inhibition of human GSNOR assessed as reduction in NADH consumption after 3 mins by spectrophotometric analysis	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.
AID601054	Inhibition of human recombinant 5HT1B receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601766	Inhibition of human recombinant ETA receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601755	Inhibition of human recombinant alpha1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645724	Plasma clearance in BALB/c mouse at 2 mg/kg, iv	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601055	Inhibition of human recombinant 5HT2A receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID621424	Inhibition of CYP3A4 at 10 uM	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601777	Inhibition of human recombinant M3 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601067	Inhibition of human recombinant chloride channel at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645726	Inhibition of S-nitrosoglutathione reductase expressed in Escherichia coli using GSNO as substrate measured for 3 mins by spectrophotometry	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601059	Inhibition of human recombinant 5HT7 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601756	Inhibition of human recombinant alpha2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID621419	Inhibition of CYP1A2 at 10 uM	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601753	Inhibition of human recombinant A2a receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645730	Toxicity in iv dosed CD-1 mouse administered qd for 4 days measured on day 5	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601069	Inhibition of human recombinant DAT at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID621421	Inhibition of CYP2C19 at 10 uM	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601065	Inhibition of human recombinant Skca channel at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601052	Inhibition of human recombinant TP receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601767	Inhibition of human recombinant GABA receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601051	Inhibition of human recombinant NOP receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601057	Inhibition of human recombinant 5HT5A receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601776	Inhibition of human recombinant M2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601058	Inhibition of human recombinant 5HT6 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601754	Inhibition of human recombinant A3 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601061	Inhibition of human recombinant VPAC1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601760	Inhibition of human recombinant BZD receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601046	Inhibition of human recombinant Y2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601064	Inhibition of human recombinant Kv channel at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601775	Inhibition of human recombinant M1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601066	Inhibition of human recombinant sodium channel at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601062	Inhibition of human recombinant V1a receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID621422	Inhibition of CYP2C19	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID621457	Oral bioavailability in BALB/c mouse at 10 mg/kg by LC/MS/MS	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601778	Inhibition of human recombinant NK2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645723	Inhibition of human recombinant delta2 opioid receptor at 10 uM by radioligand displacement assay	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601047	Inhibition of human recombinant NTS1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645725	Oral bioavailability in BALB/c mouse at 10 mg/kg	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601056	Inhibition of human recombinant 5HT3 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601044	Inhibition of human recombinant NK3 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645722	Mutagenic activity in Salmonella Typhimurium	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601768	Inhibition of human recombinant GAL2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645734	Antiasthmatic activity in ovalbumin-sensitized BALB/c mouse assessed as inhibition of methacholine-induced bronchoconstriction at >/= 0.01 mg/kg, iv administered prior to metacholine-challenge by whole body plethysmography	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601769	Inhibition of human recombinant CXCR2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601770	Inhibition of human recombinant CCR1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601070	Inhibition of human recombinant 5HT transporter at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645728	Inhibition of CYP2C19	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID621423	Inhibition of CYP2D6 at 10 uM	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601758	Inhibition of human recombinant beta2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601050	Inhibition of human recombinant MOP receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601045	Inhibition of human recombinant Y1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601049	Inhibition of human recombinant KOP receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645731	Toxicity in po dosed CD-1 mouse administered qd for 4 days measured on day 5	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID645729	Inhibition of human ERG	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601063	Inhibition of human recombinant L-type Ca2+ channel at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601764	Inhibition of human recombinant D1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601765	Inhibition of human recombinant D2S receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601759	Inhibition of human recombinant AT1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645732	Antiasthmatic activity in ovalbumin-sensitized BALB/c mouse assessed as inhibition of methacholine-induced bronchoconstriction at >/= 0.01 mg/kg, iv administered from 30 mins to 48 hrs prior to metacholine-challenge by whole body plethysmography	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601053	Inhibition of human recombinant 5HT1A receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601060	Inhibition of human recombinant sst receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601762	Inhibition of human recombinant CB1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645736	Antiinflammatory activity in C57B1/6 mouse IBD model assessed as inhibition of DSS-induced inflammatory response at 1 mg/kg, iv or po administered for 10 days from 2 days prior to and up to 2 days post DSS-challenge	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID621454	Binding affinity to human recombinant delta2 opiate receptor by radioligand displacement assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601772	Inhibition of human recombinant H2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601763	Inhibition of human recombinant CCK1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID621458	Plasma clearance in BALB/c mouse at 2 mg/kg, iv by LC/MS/MS	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID645733	Antiasthmatic activity in ovalbumin-sensitized iv dosed BALB/c mouse assessed as inhibition of methacholine-induced bronchoconstriction administered from 30 mins to 48 hrs prior to metacholine-challenge by whole body plethysmography	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601749	Inhibition of GSNOR expressed in Escherichia coli using GSNO by plate method	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601761	Inhibition of human recombinant B2 bradykinin receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601773	Inhibition of human recombinant MC4 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645735	Antiasthmatic activity in ovalbumin-sensitized BALB/c mouse assessed as inhibition of ovalbumin-induced easonophil infiltration in lungs at >/= 0.0005 mg/kg, iv administered from 30 mins to 72 hrs prior to assessment by light microscopy	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID601048	Inhibition of human recombinant Dop delta2 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID645737	Antiinflammatory activity in C57B1/6 mouse IBD model assessed as inhibition of DSS-induced inflammatory response at 10 mg/kg, iv or po administered for 10 days from 2 days prior to and up to 2 days post DSS-challenge	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
AID621420	Inhibition of CYP2C9 at 10 uM	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601068	Inhibition of human recombinant NET at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID601771	Inhibition of human recombinant H1 receptor at 10 uM by radioligand binding assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
AID621418	Inhibition of S-nitrosoglutathione reductase expressed in Escherichia coli after 3 mins by UV/Vis spectrophotometry	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
AID601490	Inhibition of GSNOR expressed in Escherichia coli using GSNO by cuvette method	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	16 (84.21)	24.3611
2020's	3 (15.79)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (5.26%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (94.74%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
propionic acid propionic acid : A short-chain saturated fatty acid comprising ethane attached to the carbon of a carboxy group.	2.98	1	0	saturated fatty acid; short-chain fatty acid	antifungal drug
methacholine chloride Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)	4.48	1	1	quaternary ammonium salt
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	7.47	14	1	pyrrole; secondary amine
cadmium Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.	2.21	1	0	cadmium molecular entity; zinc group element atom
s-nitrosoglutathione [no description available]	6.4	8	1	glutathione derivative; nitrosothio compound	bronchodilator agent; nitric oxide donor; platelet aggregation inhibitor; signalling molecule
roflumilast [no description available]	2.17	1	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.07	1	0
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.17	1	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Asthma, Bronchial [description not available]	0	5.96	5	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.08	4	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	1	7.96	5	1
Airflow Obstruction, Chronic [description not available]	0	2.17	1	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	0	2.17	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	0	2.21	1	0
Brain Swelling [description not available]	0	2.21	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	0	2.21	1	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	0	2.21	1	0
Apoplexy [description not available]	0	2.25	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	2.25	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	2.25	1	0
Labor, Premature [description not available]	0	2.17	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.17	1	0
Bronchial Hyperreactivity Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.	0	9.48	1	1
Innate Inflammatory Response [description not available]	0	2.54	2	0
Infections, Picornaviridae [description not available]	0	2.21	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.54	2	0
Injury, Myocardial Reperfusion [description not available]	0	2.17	1	0
Centriacinar Emphysema [description not available]	0	2.15	1	0
Acute Disease Disease having a short and relatively severe course.	0	2.07	1	0

n6022

Description

Cross-References

Synonyms (35)

Research Excerpts

Overview

Treatment

Bioavailability

Protein Targets (11)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (97)

Molecular Functions (65)

Ceullar Components (28)

Bioassays (87)

Research

Studies (19)

Market Indicators

Research Demand Index: 23.11

Study Types

n6022

Description

Cross-References

Synonyms (35)

Research Excerpts

Overview

Treatment

Bioavailability

Protein Targets (11)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (97)

Molecular Functions (65)

Ceullar Components (28)

Bioassays (87)

Research

Studies (19)

Market Indicators

Research Demand Index: 23.11

Study Types

Related Drugs (8)

Related Conditions (23)